CasNo.868540-17-4,99% up by HPLC Carfilzomib 868540-17-4,(868540-17-4) Suppliers

0 Metric Ton	Negotiable

Min.Order :0 Metric Ton
Purity: 99% up by HPLC

Keywords

Carfilzomib Carfilzomib powder 868540-17-4

Quick Details

Appearance:
Application:API
PackAge:
ProductionCapacity:|Metric Ton|Day
Storage:
Transportation:

Superiority:

Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial since 1987
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different t

Details:

Product name	Carfilzomib
CAS No.	868540-17-4
Molecular Formula	C₄₀H₅₇N₅O₇
Molecular Weight	719.922
Molecular Structure
Quality Standard	98% up by HPLC
Appearance	White powder

COA of Carfilzomib

ITEM	SPECIFICATION	RESULTS
Appearance	White powder	Complies
Identification	IR, UF, HPLC. In comparison with Carfilzomib RS	Complies
Melting point(the Range of temperature≤4℃ )	230 ℃	230 ℃
Solubility	slightly soluble in water and in alchohol, freely soluble in acetic acid and in methanol	Complies
Heavy metal	0.001% - 0.002%	Complies
Loss on Drying	≤1.0%	0.23%
Residue on ignition	≤1.0%	0.08%
Residual organic solvents	Ranged I and II toxic class	Complies
Total impurities	≤1.0%	0.54%
Assay (by HPLC)	≥ 98.0%	98.96%
Conclusion	The results conforms with enterprise standard.

Studies have shown that lenalidomide combined with dexamethasone plus carfilzomib has unprecedented efficacy in the treatment of relapsed multiple myeloma. The three-drug combination therapy for patients with first relapsed multiple myeloma has a progression-free survival of more than two years, which confirms the efficacy of the three-drug combination. Although the interim data analysis of this trial did not yield median overall survival in either group, the addition of carfilzomib trended toward longer overall survival (73.3% in the added carfilzomib group and 65% in the control group). ), this test result did not exceed the statistical range set by the statistician at the beginning of the experiment. More importantly, the addition of carfilzomib did not significantly increase toxicity, and the quality of life score was also higher than that of the control group. Another important information brought by this trial is that the total effective rate of the three-drug combination is significantly higher than that of the two-drug combination, 87.4% and 66.9% in the two groups, respectively; the complete remission rate of the three-drug combination is more than 3 times higher, and the two Groups were 31.8% and 9.4%, respectively. By adding carfilzomib to the gold standard for the treatment of multiple myeloma, unprecedented duration of response was seen without increased toxicity, which holds great promise for relapsed and high-dose preconditioning patients. These results may establish